Particularly, nuclear EGFR induced by EGF or PGE2 or the combination of treatments, promotes CCND1, PTGS2, MYC and NOS2 upregulation and sustains tumor growth (Figure 9), supporting the hypothesis that the gene signature associated with nuclear EGFR is correlated with poor prognosis in NSCLC and may serve as a biomarker for patients outcome and treatment selection. Here, EGFR is linked to neoplasm.